Search Within

Monica Jignesh Shah

Formats
  1. Meeting Abstract (4)
Groups
  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Population Sciences Research Program (4)
  5. Adult Leukemia (3)
  6. Biostatistics Service (3)

More Groups

People
  1. Andriy Derkach (3)
  2. Lindsey Roeker (3)
  3. Meghan Thompson (3)
  4. Aaron Goldberg (2)
  5. Andrew Zelenetz (2)
  6. Anita Kumar (2)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2017 (1)
Publications
  1. Blood (4)
Publishers
  1. American Society of Hematology (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of therapies following discontinuation of non-covalent Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study
    Meeting Abstract

    Thompson, M. C.; Bhat, S. A.; Jurczak, W.; Patel, K.; Shah, N. N.; Woyach, J. A.; Coombs, C. C.; Eyre, T. A.; Danecki, M.; Dlugosz-Danecka, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; more...
    Blood (2017)

    Fulltext@MSK | Save